Table I.
Association of clinicopathological variables of ESCC patients and PAX9 expression in tumor tissue samples.
| PAX9 | ||||
|---|---|---|---|---|
| Clinicopathological characteristics | Total patients (n=229) | Negative (n=108) (%) | Positive (n=121) (%) | P-value |
| Gender | 0.801 | |||
| Male | 185 | 88 (47.6 | 97 (52.4 | |
| Female | 44 | 20 (45.5 | 24 (54.5 | |
| Age | 0.383 | |||
| ≤60 | 116 | 58 (50.0 | 58 (50.0 | |
| >60 | 113 | 50 (44.2 | 63 (55.8 | |
| Smoking history | 0.179 | |||
| Never or light | 108 | 56 (51.9 | 52 (48.1 | |
| Heavy | 121 | 52 (43.0 | 69 (57.0 | |
| Drinking history | 0.052 | |||
| Never or light | 118 | 63 (53.3 | 55 (46.7 | |
| Heavy | 111 | 45 (40.5 | 66 (59.5 | |
| Site of tumor | 0.287 | |||
| Cervical | 7 | 2 (28.6 | 5 (71.4 | |
| Upper thoracic | 16 | 9 (56.3 | 7 (43.7 | |
| Middle thoracic | 130 | 56 (43.1 | 74 (56.9 | |
| Lower thoracic | 76 | 41 (53.9 | 35 (46.1 | |
| Tumor length | 0.941 | |||
| <4 cm | 102 | 46 (45.1 | 56 (54.9 | |
| ≥4 cm | 127 | 62 (48.8 | 65 (51.2 | |
| Differentiation | 0.893 | |||
| Well | 55 | 25 (45.5 | 30 (54.5 | |
| Moderate | 99 | 46 (46.5 | 53 (53.5 | |
| Poor | 75 | 37 (49.3 | 38 (50.7 | |
| T stage | 0.150 | |||
| T1 | 23 | 6 (26.1 | 17 (73.9 | |
| T2 | 65 | 31 (47.7 | 34 (52.3 | |
| T3 | 126 | 62 (49.2 | 64 (50.8 | |
| T4 | 15 | 9 (60.0 | 6 (40.0 | |
| N stage | 0.162 | |||
| N0 | 120 | 51 (42.5 | 69 (57.5 | |
| N1 | 87 | 45 (51.7 | 42 (48.3 | |
| N2 | 19 | 9 (47.4 | 10 (52.6 | |
| N3 | 3 | 3 (100.0 | 0 (0.00 | |
| pTNM stage | 0.105 | |||
| I | 26 | 10 (38.5 | 16 (61.5 | |
| II | 101 | 42 (41.6 | 59 (58.4 | |
| III | 102 | 56 (54.9 | 46 (45.1 | |
| Adjuvant treatment | 0.060 | |||
| None | 110 | 55 (50.0 | 55 (50.0 | |
| Radiotherapy | 66 | 24 (36.4 | 42 (63.6 | |
| Chemotherapy | 18 | 7 (38.9 | 11 (61.1 | |
| CRT | 35 | 22 (62.9 | 13 (37.1 | |
T, tumor; N, node; PAX9, paired box 9; TNM, tumor node metastasis; ESCC, esophageal squamous cell carcinoma; CRT, chemoradiotherapy.